Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More

  |  Issue: March 2021  |  

Pfizer continues to examine data for the rates of pulmonary embolism and other secondary endpoints points. The company is working with the FDA to review the study’s full results as more information becomes available.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Pfizer Inc. News release: Pfizer shares co-primary endpoint results from post-marketing required safety study of Xeljanz (tofacitinib) in subjects with rheumatoid arthritis (RA). 2021 Jan 27.
  2. U.S. Food & Drug Administration. Center for drug evaluation and research application number: 203214 (Xeljanz) Orig1s000 approval letter. 2021 Nov 6
  3. U.S. Food & Drug Administration. Highlights of prescribing information: Xeljanz (tofacitinib). 2020 Nov.
  4. U.S. Food & Drug Administration. Supplement approval letter Xeljanz (tofacitinib). 2019 July 25.
  5. Pfizer Inc. Safety study of tofacitinib vs. tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis (NCT02092467). Clinicaltrials.gov. 2021 Jan 28.

Related Articles

    Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

    ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

    Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

    Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Are We Playing It Safe?

    Tumor necrosis factor alpha inhibition and the risk of solid malignancies